|
| 产品描述 |
| Tanzisertib, also known as CC-930, is a potent, selective, and orally active JNK inhibitor with potential antifibrotic activity. CC-930 entered Phase I clinical trials. Tanzisertib may have potential use for prevention and treatment of dermal fibrosis. Selective inhibition of JNK by CC-930 exerted potent antifibrotic effects in vitro and in different models in vivo. JNK might thus be a novel molecular target for the treatment of fibrosis in SSc. |
| 化学结构 |
 |
| 化学名称 |
| (1S,4r)-4-((9-((S)-tetrahydrofuran-3-yl)-8-((2,4,6-trifluorophenyl)amino)-9H-purin-2-yl)amino)cyclohexanol |
| SMILES Code |
| O[C@H]1CC[C@H](NC2=NC=C3N=C(NC4=C(F)C=C(F)C=C4F)N([C@@H]5COCC5)C3=N2)CC1. |
| 基本信息 |
产品编号:XM122
产品名称:Tanzisertib (CC-930)
CAS#:899805-25-5
分子式:C21H23F3N6O2
精确分子量:448.18346
分子量:448.44
纯度:>98%
|
| 物化性质 |
外观: 固体粉末
纯度: >98%
运输信息: 非危险化学品，适于常温或冰袋运输。
储存条件: 低温，干燥，避光。
溶解性: 溶于DMSO, 不溶于水
储存期限: 3 年 -20℃ 固体储存 2 年 -80℃ 溶液储存 |
该产品只供科研使用，不能给病人提供。
|
|
|
